Stacian Gallimore-King
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.5% of the total across 57 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,694 and has fallen 55.9% since, to $747 in 2025. Among family clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 57 payments — averaging $100.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$1K
- Johnson & Johnson$860
- AstraZeneca$735
- Seagen Inc.$501
- Merck$279
- Mirati Therapeutics, Inc.$257
- plus $2K from 16 others
What the payments were for
- Food & beverage$5,44796%
- Education$2564%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 9 | $1,106 |
| Johnson & Johnson | 7 | $860 |
| AstraZeneca | 6 | $735 |
| Seagen Inc. | 5 | $501 |
| Merck | 4 | $279 |
| Mirati Therapeutics, Inc. | 2 | $257 |
| Puma Biotechnology, Inc. | 2 | $250 |
| Bristol Myers Squibb | 2 | $245 |
| Jazz Pharmaceuticals Inc. | 3 | $195 |
| G1 Therapeutics, Inc. | 1 | $145 |
| Taiho Oncology, Inc. | 1 | $125 |
| Amgen | 1 | $125 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| Incyte Corporation | 1 | $124 |
| Exelixis Inc. | 1 | $122 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $122 |
| Karyopharm Therapeutics Inc. | 1 | $122 |
| Gilead | 1 | $94 |
| Lilly USA, LLC | 4 | $91 |
| Tersera Therapeutics LLC | 2 | $34 |
| Intuitive Surgical | 1 | $23 |
| Deciphera Pharmaceuticals Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,703 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LenvimaLenvatinib Mesylate | 12 | $288,233 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $362 |
| Lidocaine Hcl ViscousLidocaine Hcl | 15 | $359 |
| Levothyroxine Sodium | 18 | $158 |
| Levetiracetam | 13 | $102 |
Paid to pharmacies, not to this prescriber.
Other family in Bronx
- Vladimir ByhovskyBronx$70K
- May YuBronx$24K
- Daphenie FauvelBronx$21K
- Schevaughn Carr CelestineBronx$20K
- Nighat SaeedBronx$19K
- Keisha BallentineBronx$18K
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.